Canada markets close in 2 hours 25 minutes

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.28-0.03 (-0.40%)
As of 01:19PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close6.30
Bid6.22 x 2200
Ask6.33 x 1200
Day's Range6.21 - 6.61
52 Week Range1.45 - 7.92
Avg. Volume254,293
Market Cap236.027M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.01
Earnings DateNov 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Simply Wall St.

    We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in second half of 2023IND-enabling activities for TERN-601 (oral GLP-1R agonist) remain on track with plans to initiate first-in-human clinical trial in obesity in 2023Cash and equivalents of $187 million provides runway into 2025, incl

  • GlobeNewswire

    Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

    Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial evaluating TERN-501 alone and in combination with TERN-101, the first trial assessing both THR-β and FXR agonists in NASH, is ongoing FOSTER CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company